Immunome's Q1 net loss widens on higher expenses

Immunome

12/05/2026 21:11

Overview

US targeted oncology firm's Q1 net loss widened as operating expenses increased

Company posted no collaboration revenue in Q1, down from $2.9 mln a year earlier

Immunome submitted NDA to FDA for varegacestat and advanced multiple oncology pipeline programs

Outlook

Immunome expects to present initial lymphoma data for IM-1021 in 2026

Company plans to submit a Marketing Authorization Application for varegacestat to EMA by end-2026

Immunome expects current cash position to fund operations into 2028

Result Drivers

NO COLLABORATION REVENUE - Co reported no collaboration revenue in Q1, down from $2.9 mln a year earlier

Company press release: ID:nBw1pwpQ5a

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Net Income
-$53.84 mln
Q1 Income From Operations
-$59.33 mln
Q1 Operating Expenses
$59.33 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 14 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Immunome Inc is $35.50, about 54.3% above its May 11 closing price of $23.00

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)